Inhibition of the renin-angiotensin system: is more better?

Sharon Anderson1, Radko Komers

  • 1Division of Nephrology and Hypertension, Oregon Health and Science University, Portland, Oregon, USA. anderssh@ohsu.edu

Kidney International
|December 19, 2008
PubMed

Insights

Losartan, a renin-angiotensin-aldosterone system inhibitor, can reduce proteinuria and reverse early mesangial expansion in diabetic nephropathy. However, it does not impact more advanced lesions or show dose-dependent effects.

Area of Science:

  • Nephrology
  • Endocrinology
  • Pharmacology

Background:

  • Diabetic nephropathy is a major complication of diabetes, characterized by progressive renal damage.
  • Inhibitors of the renin-angiotensin-aldosterone system (RAS) are known to slow the progression of diabetic kidney disease.
  • The potential for RAS inhibitors to reverse existing renal lesions in diabetic nephropathy requires further investigation.

Discussion:

  • This study investigated the effects of losartan, a RAS inhibitor, on established renal lesions in a rat model of diabetes.
  • The findings suggest that losartan can lead to a regression of mesangial expansion, a key feature of diabetic nephropathy.
  • However, the study also indicated that losartan did not affect more advanced renal lesions and showed no dose-response relationship.

Key Insights:

  • Losartan treatment in rats with established diabetic nephropathy reduced proteinuria.
  • The reduction in proteinuria was associated with the regression of mesangial expansion.
  • Advanced renal lesions in diabetic nephropathy were not reversed by losartan treatment.

Outlook:

  • Further research is needed to explore therapeutic strategies for reversing advanced renal lesions in diabetic nephropathy.
  • Investigating combination therapies or alternative treatments may be beneficial for patients with advanced disease.
  • Understanding the mechanisms underlying lesion regression and progression is crucial for developing effective interventions.

Related Concept Videos

Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...